Researchers have developed a machine learning-based gene signature, NPC-RSS, to predict which nasopharyngeal cancer patients will benefit from radiotherapy.
Key Details
- 1A team at Southern Medical University created the NPC-RSS model using transcriptomic data from NPC patients.
- 2The model uses an 18-gene signature and was refined using 113 machine learning algorithm combinations.
- 3NPC-RSS demonstrated strong predictive accuracy in both internal and external validation datasets.
- 4Radiosensitive tumors showed richer immune cell activity, suggesting immune dynamics play a role in radiotherapy response.
- 5The tool aims to guide personalized radiotherapy decisions and reduce unnecessary treatment exposure.
- 6Further sample collection and international validation are ongoing to refine the model.
Why It Matters
Personalized radiotherapy guided by AI can improve outcomes in nasopharyngeal cancer by identifying patients most likely to benefit, addressing the challenge of radiation resistance. This tool could help clinicians tailor therapies, limit overtreatment, and improve patient survival.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.